Adult Vaccine Market Report: Market Size & Forecast 2026

The adult vaccines market covers immunizations targeting diseases prevalent in adolescent and adult populations, including influenza, pneumococcal disease, HPV, herpes zoster, meningococcal disease, and travel-related infections. The market was valued at approximately $23.66 billion in 2025 and reached $25.099 billion in 2026, with steady expansion projected through 2031. The market encompasses both well-established vaccine products with decades of use and newer formulations addressing previously unmet needs in adult immunization.

Aging populations in developed and developing nations represent the primary growth catalyst, as older adults face higher risks from diseases like shingles, pneumococcal infections, and influenza. Increased awareness among healthcare providers and patients regarding the importance of adult vaccination, combined with routine recommendations from public health authorities, has expanded the eligible vaccinated population. Advances in vaccine technology, including mRNA platforms, adjuvanted formulations, and improved storage stability, have enabled new product launches and enhanced protection across broader age groups.

The market is segmented by vaccine type, with influenza vaccines representing the largest segment due to annual recommendations for broad adult populations, followed by pneumococcal, HPV, and shingles vaccines as high-growth categories. North America currently commands the largest market share, supported by comprehensive healthcare infrastructure, favorable reimbursement policies, and high vaccination adoption rates. Europe and Asia-Pacific constitute significant markets, with Asia-Pacific showing particularly strong growth potential due to rising healthcare expenditures, expanding insurance coverage, and government initiatives to increase adult vaccination rates in countries such as China, India, and Japan.

What are the recent trends and outlook?

The market is witnessing a shift toward combination vaccines that protect against multiple pathogens in single administrations, reducing healthcare visit burden and improving adherence. Ongoing innovation in delivery systems, digital health integration, and real-time surveillance is further enhancing vaccination program efficiency and coverage.